{"id":"https://openalex.org/W7133258554","doi":"https://doi.org/10.1200/jco.2026.44.7_suppl.747","title":"Nivolumab and ipilimumab maintenance therapy for advanced or metastatic urothelial carcinoma: Final results from SOGUG-VEXILLUM trial.","display_name":"Nivolumab and ipilimumab maintenance therapy for advanced or metastatic urothelial carcinoma: Final results from SOGUG-VEXILLUM trial.","publication_year":2026,"publication_date":"2026-03-01","ids":{"openalex":"https://openalex.org/W7133258554","doi":"https://doi.org/10.1200/jco.2026.44.7_suppl.747"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2026.44.7_suppl.747","doi":"https://doi.org/10.1200/jco.2026.44.7_suppl.747","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2026.44.7_suppl.747","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5101773564","display_name":"Guillermo de Velasco","orcid":"https://orcid.org/0000-0002-8075-0666","observed_orcids":["https://orcid.org/0000-0002-8075-0666"]},"institutions":[{"id":"https://openalex.org/I4210101691","display_name":"Hospital Universitario 12 De Octubre","ror":"https://ror.org/00qyh5r35","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210101691","https://openalex.org/I4210139293"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Guillermo de Velasco","raw_affiliation_strings":["University Hospital 12 de Octubre, Madrid, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University Hospital 12 de Octubre, Madrid, Spain","institution_ids":["https://openalex.org/I4210101691"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023560654","display_name":"Iciar Garc\u00eda Carbonero","orcid":"https://orcid.org/0000-0003-1044-701X","observed_orcids":["https://orcid.org/0000-0003-1044-701X"]},"institutions":[{"id":"https://openalex.org/I4210111854","display_name":"Hospital Virgen de la Salud","ror":"https://ror.org/0289cxp23","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210111854","https://openalex.org/I4210141158","https://openalex.org/I4210163156","https://openalex.org/I4392738192"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Iciar Garc\u00eda Carbonero","raw_affiliation_strings":["Medical Oncology Department. Hospital Hospital Virgen de la Salud, Toledo, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology Department. Hospital Hospital Virgen de la Salud, Toledo, Spain","institution_ids":["https://openalex.org/I4210111854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041104141","display_name":"Carlos \u00c1lvarez-Fern\u00e1ndez","orcid":"https://orcid.org/0000-0002-2500-074X","observed_orcids":["https://orcid.org/0000-0002-2500-074X","https://orcid.org/0000-0002-5766-505X"]},"institutions":[{"id":"https://openalex.org/I4210133994","display_name":"Hospital Universitario Central de Asturias","ror":"https://ror.org/03v85ar63","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I2800212897","https://openalex.org/I4210133994","https://openalex.org/I4405258403"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Carlos Alvarez-Fernandez","raw_affiliation_strings":["Medical Oncology Department. Hospital Universitario Central de Asturias, Oviedo, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology Department. Hospital Universitario Central de Asturias, Oviedo, Spain","institution_ids":["https://openalex.org/I4210133994"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103851506","display_name":"Rebeca Lozano","orcid":"https://orcid.org/0000-0001-9567-6385","observed_orcids":["https://orcid.org/0000-0001-9567-6385"]},"institutions":[{"id":"https://openalex.org/I4210099034","display_name":"Complejo Hospitalario de Salamanca","ror":"https://ror.org/0131vfw26","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I184999862","https://openalex.org/I4210099034"]},{"id":"https://openalex.org/I4210134045","display_name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca","ror":"https://ror.org/03em6xj44","country_code":"ES","type":"facility","lineage":["https://openalex.org/I184999862","https://openalex.org/I4210099034","https://openalex.org/I4210134045"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Rebeca Lozano","raw_affiliation_strings":["Complejo Asistencial Universitario de Salamanca; Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Complejo Asistencial Universitario de Salamanca; Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain","institution_ids":["https://openalex.org/I4210099034","https://openalex.org/I4210134045"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044448918","display_name":"Urbano Anido Herranz","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Urbano Anido Herranz","raw_affiliation_strings":["Molecular Imaging Research Group, Nuclear Medicine Department. University Clinical Hospital of Santiago de Compostela, Santiago De Compostela, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Molecular Imaging Research Group, Nuclear Medicine Department. University Clinical Hospital of Santiago de Compostela, Santiago De Compostela, Spain","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5096599515","display_name":"\u00d2scar Ribas Reig","orcid":"https://orcid.org/0000-0003-1166-6943","observed_orcids":["https://orcid.org/0000-0003-1166-6943"]},"institutions":[{"id":"https://openalex.org/I4210160192","display_name":"Consorci Institut D'Investigacions Biomediques August Pi I Sunyer","ror":"https://ror.org/054vayn55","country_code":"ES","type":"facility","lineage":["https://openalex.org/I4210115097","https://openalex.org/I4210160192","https://openalex.org/I4387153040","https://openalex.org/I4403928279"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Oscar Reig","raw_affiliation_strings":["Medical Oncology, Hospital Clinic and Translational Genomics and Targeted Therapies in Solid Tumors Group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Hospital Clinic and Translational Genomics and Targeted Therapies in Solid Tumors Group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain","institution_ids":["https://openalex.org/I4210160192"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5099776869","display_name":"Francisco Jos\u00e9 \u00c1lvarez-M\u00e1rquez","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210129320","display_name":"Hospital Juan Ram\u00f3n Jim\u00e9nez","ror":"https://ror.org/03fpqn433","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I158283456","https://openalex.org/I4210129320"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Francisco Jos\u00e9 \u00c1lvarez-M\u00e1rquez","raw_affiliation_strings":["Medical Oncology Department. Hospital Universitario Juan Ram\u00f3n Jim\u00e9nez, Huelva, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology Department. Hospital Universitario Juan Ram\u00f3n Jim\u00e9nez, Huelva, Spain","institution_ids":["https://openalex.org/I4210129320"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071946051","display_name":"Pablo Gajate","orcid":"https://orcid.org/0000-0001-5156-7080","observed_orcids":["https://orcid.org/0000-0001-5156-7080"]},"institutions":[{"id":"https://openalex.org/I4210127475","display_name":"Instituto Ram\u00f3n y Cajal de Investigaci\u00f3n Sanitaria","ror":"https://ror.org/03fftr154","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210127475"]},{"id":"https://openalex.org/I4210161852","display_name":"Hospital Universitario Ram\u00f3n y Cajal","ror":"https://ror.org/050eq1942","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210139293","https://openalex.org/I4210161852"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Pablo Gajate","raw_affiliation_strings":["Medical Oncology, Hospital Universitario Ram\u00f3n y Cajal, Instituto Ram\u00f3n y Cajal de Investigaci\u00f3n Sanitaria (IRYCIS), Madrid, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology, Hospital Universitario Ram\u00f3n y Cajal, Instituto Ram\u00f3n y Cajal de Investigaci\u00f3n Sanitaria (IRYCIS), Madrid, Spain","institution_ids":["https://openalex.org/I4210127475","https://openalex.org/I4210161852"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5127789030","display_name":"Marina Justo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210152826","display_name":"Hospital Universitario Son Espases","ror":"https://ror.org/05jmd4043","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210152826"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Marina Justo","raw_affiliation_strings":["Medical Oncology Department. Hospital Universitario Son Espases, Mallorca, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology Department. Hospital Universitario Son Espases, Mallorca, Spain","institution_ids":["https://openalex.org/I4210152826"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102474031","display_name":"A. Samaniego Torres","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210090436","display_name":"Hospital Universitario Virgen Macarena","ror":"https://ror.org/016p83279","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210090436"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Alberto Torres","raw_affiliation_strings":["Medical Oncology Department. Hospital Universitario Virgen de la Macarena, Sevilla, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology Department. Hospital Universitario Virgen de la Macarena, Sevilla, Spain","institution_ids":["https://openalex.org/I4210090436"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001131997","display_name":"Eduardo Pujol","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210135032","display_name":"Hospital Cl\u00ednico Universitario Lozano Blesa","ror":"https://ror.org/03fyv3102","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210135032"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Eduardo Pujol","raw_affiliation_strings":["Medical Oncology Department. Hospital Cl\u00ednico Universitario Lozano Blesa, Zaragoza, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology Department. Hospital Cl\u00ednico Universitario Lozano Blesa, Zaragoza, Spain","institution_ids":["https://openalex.org/I4210135032"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5104124627","display_name":"Aina Iranzo Sabater","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210094134","display_name":"Hospital de La Ribera","ror":"https://ror.org/00qnmxq60","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210094134"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Aina Iranzo","raw_affiliation_strings":["Medical Oncology Department. Hospital Universitario de la Ribera, Alzira (Valencia), Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology Department. Hospital Universitario de la Ribera, Alzira (Valencia), Spain","institution_ids":["https://openalex.org/I4210094134"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":13,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"44","issue":"7_suppl","first_page":"747","last_page":"747"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10458","display_name":"Bladder and Urothelial Cancer Treatments","score":0.9409000277519226,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10458","display_name":"Bladder and Urothelial Cancer Treatments","score":0.9409000277519226,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.05620000138878822,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10449","display_name":"Renal cell carcinoma treatment","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/urothelial-carcinoma","display_name":"urothelial carcinoma","score":0.8679999709129333},{"id":"https://openalex.org/keywords/maintenance-therapy","display_name":"maintenance therapy","score":0.6330000162124634},{"id":"https://openalex.org/keywords/nivolumab","display_name":"nivolumab","score":0.9900000095367432},{"id":"https://openalex.org/keywords/ipilimumab","display_name":"ipilimumab","score":1.0},{"id":"https://openalex.org/keywords/ctla-4","display_name":"CTLA-4","score":0.671999990940094},{"id":"https://openalex.org/keywords/pd-1","display_name":"PD-1","score":0.8880000114440918},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.8700000047683716},{"id":"https://openalex.org/keywords/first-line-platinum-based-chemotherapy","display_name":"first-line platinum-based chemotherapy","score":0.7250000238418579},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.902999997138977},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.7829999923706055},{"id":"https://openalex.org/keywords/pd-l1-expression","display_name":"PD-L1 expression","score":0.8930000066757202},{"id":"https://openalex.org/keywords/enfortumab-vedotin","display_name":"enfortumab vedotin","score":0.824999988079071},{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":0.9760000109672546}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9467999935150146},{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.9049000144004822},{"id":"https://openalex.org/C2781433595","wikidata":"https://www.wikidata.org/wiki/Q2459042","display_name":"Ipilimumab","level":4,"score":0.8877999782562256},{"id":"https://openalex.org/C2778283404","wikidata":"https://www.wikidata.org/wiki/Q6736822","display_name":"Maintenance therapy","level":3,"score":0.7243000268936157},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6902999877929688},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6758000254631042},{"id":"https://openalex.org/C2781451048","wikidata":"https://www.wikidata.org/wiki/Q415588","display_name":"Carboplatin","level":4,"score":0.6732000112533569},{"id":"https://openalex.org/C2780258809","wikidata":"https://www.wikidata.org/wiki/Q414143","display_name":"Gemcitabine","level":3,"score":0.5906000137329102},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.5370000004768372},{"id":"https://openalex.org/C146357865","wikidata":"https://www.wikidata.org/wiki/Q1123245","display_name":"Stage (stratigraphy)","level":2,"score":0.4528999924659729},{"id":"https://openalex.org/C2780352672","wikidata":"https://www.wikidata.org/wiki/Q504775","display_name":"Bladder cancer","level":3,"score":0.43540000915527344},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.42570000886917114},{"id":"https://openalex.org/C2911057145","wikidata":"https://www.wikidata.org/wiki/Q2501186","display_name":"Metastatic Urothelial Carcinoma","level":5,"score":0.3831000030040741},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3441999852657318},{"id":"https://openalex.org/C2778239845","wikidata":"https://www.wikidata.org/wiki/Q412415","display_name":"Cisplatin","level":3,"score":0.3398999869823456},{"id":"https://openalex.org/C3020745361","wikidata":"https://www.wikidata.org/wiki/Q2501186","display_name":"Urothelial cancer","level":4,"score":0.3375999927520752},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.311599999666214},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.29910001158714294},{"id":"https://openalex.org/C2779984678","wikidata":"https://www.wikidata.org/wiki/Q2145898","display_name":"Response Evaluation Criteria in Solid Tumors","level":4,"score":0.2922999858856201},{"id":"https://openalex.org/C2776283816","wikidata":"https://www.wikidata.org/wiki/Q332823","display_name":"Survival rate","level":2,"score":0.28459998965263367},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.2842000126838684},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.28139999508857727},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.27950000762939453},{"id":"https://openalex.org/C2776907518","wikidata":"https://www.wikidata.org/wiki/Q1734165","display_name":"Performance status","level":3,"score":0.27300000190734863},{"id":"https://openalex.org/C2775949291","wikidata":"https://www.wikidata.org/wiki/Q20707748","display_name":"Atezolizumab","level":5,"score":0.26980000734329224},{"id":"https://openalex.org/C509974204","wikidata":"https://www.wikidata.org/wiki/Q180507","display_name":"Radiation therapy","level":2,"score":0.2655999958515167},{"id":"https://openalex.org/C2777546739","wikidata":"https://www.wikidata.org/wiki/Q33525","display_name":"Carcinoma","level":2,"score":0.259799987077713}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2026.44.7_suppl.747","doi":"https://doi.org/10.1200/jco.2026.44.7_suppl.747","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2026.44.7_suppl.747","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4400187087","https://openalex.org/W4396769404","https://openalex.org/W6967079941","https://openalex.org/W4322604110","https://openalex.org/W2582671354","https://openalex.org/W3135034545","https://openalex.org/W4220822501","https://openalex.org/W4387859553","https://openalex.org/W4324136729","https://openalex.org/W3164197656"],"abstract_inverted_index":{"747":[0],"Background:":[1],"The":[2,59,86,217,271,380],"pioneering":[3],"study":[4,40,60],"was":[5,10,89,108,164,220,236,263,274],"designed":[6],"when":[7],"platinum-based":[8,53],"chemotherapy":[9],"the":[11,27,94,100,117,135,147,151,155,160,168,233,242,260,297,306,335,350],"standard":[12,173],"of":[13,29,63,66,96,150,170,174,299,310,367,385],"care":[14,175],"for":[15,116],"advanced":[16],"urothelial":[17,45],"carcinoma":[18],"and":[19,71,102,138,194,197,225,244,253,259,285,294,313,345,399,404],"evaluated":[20],"whether":[21],"dual":[22,354,386],"ICI":[23,355,387],"(CTL4-PD1)":[24],"could":[25],"improve":[26],"benefit":[28],"maintenance":[30,83,97,199,356,391],"therapy":[31,84,98],"in":[32,99,134,142,180,208,214,321,330,393],"this":[33,181,394],"setting.":[34,182],"Methods:":[35],"This":[36],"unique":[37],"single-arm,":[38],"multicentre":[39],"included":[41,193],"patients":[42,133,191,210,290,303,323,332,368],"with":[43,203,206,280,334,357,365],"unresectable":[44],"cancer":[46],"that":[47],"did":[48],"not":[49],"progress":[50],"after":[51,200],"first-line":[52,201],"CT":[54,202],"(at":[55],"least":[56],"4-6":[57],"cycles).":[58],"treatment":[61],"consisted":[62],"four":[64],"cycles":[65],"ipilimumab":[67,198],"(ipi)":[68],"3":[69,76],"mg/kg":[70,74],"nivo":[72,358],"1":[73],"every":[75],"weeks":[77],"(Q3W),":[78],"followed":[79],"by":[80],"nivolumab":[81,196],"(nivo)":[82],"(Q4W).":[85],"primary":[87],"endpoint":[88],"progression-free":[90],"survival":[91],"(PFS)":[92],"from":[93,296,377],"start":[95,298],"overall":[101],"PD-L1":[103],"positive":[104],"populations.":[105],"Sample":[106],"size":[107],"estimated":[109],"using":[110],"a":[111,171,389],"Simon":[112],"II":[113],"stage":[114,137,162],"design":[115],"4-months":[118],"PFS":[119,246,262],"rate":[120],"(H0=":[121],"40%;":[122],"H1=":[123],"60%;":[124],"\u03b1":[125],"=":[126,129],"0.05;":[127],"\u03b2":[128],"90%),":[130],"requiring":[131],"25":[132,190],"1st":[136],"up":[139],"to":[140,157,159,187,319],"66":[141],"total.":[143],"Here,":[144],"we":[145],"report":[146],"final":[148],"results":[149],"study,":[152],"which":[153],"met":[154],"criteria":[156],"proceed":[158],"second":[161],"but":[163],"prematurely":[165],"closed":[166],"following":[167],"emergence":[169],"new":[172],"(enfortumab":[176],"vedotin":[177],"+":[178],"pembrolizumab)":[179],"Results:":[183],"From":[184],"Sep":[185],"2022":[186],"Apr":[188],"2024,":[189],"were":[192,227,248,315,328],"received":[195],"gemcitabine":[204],"combined":[205],"cisplatin":[207],"14":[209],"(56%)":[211],"or":[212],"carboplatin":[213],"11":[215],"(44%).":[216],"median":[218,234,261,272],"age":[219],"64":[221],"years":[222,309],"(range:":[223],"53-79)":[224],"most":[226,336],"male":[228],"(80%).":[229],"At":[230],"data":[231],"cutoff,":[232],"follow-up":[235],"24":[237],"months":[238,265,276],"(95%":[239,250,255,266,277,282,287],"CI:":[240,251,256,267,278,283,288],"7-25.3),":[241],"1-":[243,293],"2-year":[245],"rates":[247],"36%":[249],"21.4-60.7)":[252],"28%":[254],"14.9-52.5),":[257],"respectively,":[258],"5.6":[264],"3.2-not":[268],"reached":[269],"[NR]).":[270],"OS":[273],"27.4":[275],"10.1-NR),":[279],"64%":[281],"47.7-85.9)":[284],"60%":[286,366],"43.6-82.6)":[289],"alive":[291,369],"at":[292,370],"2-years":[295],"nivo/ipi,":[300],"respectively.":[301],"Five":[302],"(20%)":[304],"completed":[305],"scheduled":[307],"2":[308,371],"treatment.":[311],"Nivo":[312],"ipi":[314,360],"permanently":[316],"discontinued":[317],"due":[318],"toxicity":[320],"4":[322],"(16%).":[324],"Grade":[325],"\u22653":[326],"toxicities":[327],"observed":[329],"10":[331],"(40%),":[333],"common":[337],"being":[338],"elevated":[339],"ALT/AST":[340],"(12%),":[341],"immune-mediated":[342],"hepatitis":[343],"(8%),":[344],"diarrhea":[346],"(8%).":[347],"Conclusions:":[348],"Despite":[349],"limited":[351],"sample":[352],"size,":[353],"plus":[359],"achieved":[361],"durable":[362],"disease":[363],"control,":[364],"years,":[372],"numerically":[373],"exceeding":[374],"historical":[375],"outcomes":[376],"PD-1/PD-L1":[378],"monotherapy.":[379],"signal":[381],"supports":[382],"further":[383],"exploration":[384],"as":[388],"potential":[390],"strategy":[392],"disease.":[395],"Comprehensive":[396],"spatial":[397],"transcriptomics":[398],"microbiome":[400],"analyses":[401],"are":[402],"ongoing":[403],"will":[405],"be":[406],"presented.":[407],"Clinical":[408],"trial":[409],"information:":[410],"NCT05219435":[411],".":[412]},"counts_by_year":[],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2026-03-03T00:00:00"}